key: cord-1029803-kc3nb2pc
authors: Lithander, Fiona E; Neumann, Sandra; Tenison, Emma; Lloyd, Katherine; Welsh, Tomas J; Rodrigues, Jonathan C L; Higgins, Julian P T; Scourfield, Lily; Christensen, Hannah; Haunton, Victoria J; Henderson, Emily J
title: COVID-19 in Older People: A Rapid Clinical Review
date: 2020-05-06
journal: Age Ageing
DOI: 10.1093/ageing/afaa093
sha: 950a743bf72ae3ffe360404a815d7a9791499312
doc_id: 1029803
cord_uid: kc3nb2pc

INTRODUCTION: The COVID-19 pandemic poses a high risk to older people. The aim of this paper is to provide a rapid overview of the COVID-19 literature, with a specific focus on older adults. We frame our findings within an overview of the disease and have also evaluated the inclusion of older people within forthcoming clinical trials. METHODS: We searched PubMed and bioRxiv/medRxiv to identify English language papers describing the testing, treatment and prognosis of COVID-19. PubMed and bioRxiv/medRxiv searches took place on 20th and 24th March 2020, respectively. RESULTS: Screening of over 1100 peer-reviewed and pre-print papers yielded n = 22 on COVID-19 testing, n = 15 on treatment and n = 13 on prognosis. Viral-PCR and serology are the mainstays of testing but a positive diagnosis may be increasingly supported by radiological findings. The current evidence for the effectiveness of antiviral, corticosteroid and immunotherapies is inconclusive, although trial data are largely based on younger people. In addition to age, male gender and comorbidities, specific laboratory and radiology findings are important prognostic factors. Evidence suggests social distancing policies could have important negative consequences, particularly if in place for an extended period. CONCLUSION: Given the established association between increasing age and poor prognosis in COVID-19, we anticipate that this rapid review of the current and emergent evidence might form a basis on which future work can be established. Exclusion of older people, particularly those with comorbidities, from clinical trials is well recognised and is potentially being perpetuated in the field of current COVID-19 research.

 Older patients have a higher mortality and may present atypically with delirium, postural instability or diarrhoea, and without fever.

 Given the lack of sensitivity of individual tests, information from different testing modalities can be incorporated to support diagnosis.

 In addition to age, male gender and presence of comorbidities, specific laboratory and radiology findings are important prognostic factors.

 Social distancing and isolation may have negative consequences for older people, unrelated to COVID-19.

 Older patients are relatively excluded from clinical trials relating to COVID-19.

In January 2020, a cluster of pneumonia cases in Wuhan City, Hubei province, China were identified as having been caused by the SARS-CoV-2 virus, leading to the disease now termed COVID-19. The subsequent global transmission led to the outbreak being classified as a pandemic by the World

Health Organisation (WHO) on 11 th March 2020. In the United Kingdom (UK), public health measures to control the spread of disease have, to date, included directives to self-isolate, socially distance, and so called 'lockdown' whereby activity and movement within a community is contained or limited.

Older adults, and those with comorbidities, are at particular risk of having severe infection [1] and In the UK and Europe, we are seeing an increasing number of cumulative cases and a rising trend in the daily number of confirmed COVID-19 cases. As such we have recognised an urgent need to provide clinicians, who may be less familiar with geriatric medicine, with a comprehensive overview of COVID-19 infection in older people. The overarching aim of this paper is to provide a rapid semisystematic review of both peer-reviewed and pre-print evidence relating to COVID-19 testing, drug treatment and prognosis, as of late March 2020. We have presented these findings within a broader context discussing clinical presentation, supportive care strategies and social distancing in older people. Our findings, coupled with evaluation of the landscape of current and future clinical trials, have highlighted areas of priority for future research directed toward COVID-19 infection in older people.

The current WHO suspected case definition is shown in Box 1 [5] . Clinical manifestations are summarised in Box 2. Cohort studies of patients with mild and moderate disease showed that fever was the most common symptom in 82-87% of cases, followed by cough in 36-66% [6] . This reflects findings from a meta-analysis of cases in China [7] where, of note, fever was more common during admission that at presentation [8] . In the RADAR COVID-19 study, in patients in a community setting with symptoms that warranted testing, anosmia was present in 59% who tested positive [9] . Other

clinical features include headache, rhinorrhoea, gastrointestinal symptoms, sore throat and fatigue.

Cardiac complications are described including myocarditis [10] , pericardial effusion on imaging [11] and arrhythmia [12] which is seen more commonly in those with greater disease severity [13] .

Patients with severe infection can develop a pro-inflammatory cytokine release syndrome which can lead to rapid deterioration and death [14] . The majority of studies to date have notably reported symptoms occurring in patients with proven infection in hospitals.

Early reports substantiate that older people with COVID-19 will likely present atypically [15] ; experience in France suggests that this group may initially present with delirium, postural instability or diarrhoea, rather than with typical respiratory symptoms and fever [16] . With COVID-19 being detected in older people who are in hospital for other illnesses, such as following a fall [16] , it remains to be determined as to what extent these index events are precipitated by COVID-19

infection versus COVID-19 being found incidentally. Atypical presentations omitted from public health campaigns, such as diarrhoea, showed a pooled incidence rate of 9.2% [17] . Limited data are available on rates of delirium in COVID-19 infection, although the risk has been identified by the WHO and the British Geriatrics Society (BGS) who have produced specific guidelines to support delirium management in this context (Box 3) [18] .

Typical findings on blood tests are lymphopenia and elevated C reactive protein (CRP) [19] . In moderate-to-severe cases increased procalcitonin levels have been observed [20] . Consistent with the aforementioned cardiac complications, severe cases often see raised levels of troponin I, Ddimer and lactate dehydrogenase [3, 12, 19, 21] . Chest radiograph (CXR) features are foci of illdefined opacification with bibasal predilection, evolving to consolidation [17, 19] . On chest computerised tomography (CT), chest typical findings include lower lobe and peripheral predominance with multiple, bilateral foci of ground glass opacity [7, 17, 22] with or without crazy- The main complication of COVID-19 is acute respiratory distress syndrome (ARDS). This is reported to occur in between 15% [7] and 23% [17] of cases. Other complications include respiratory failure [27] , acute kidney injury [27, 28] , and liver dysfunction [28] . Described causes of death include pneumonia, multi-organ failure, and severe acute respiratory syndrome [3, 19] .

There is a striking paucity of peer reviewed evidence that examines the specific characteristics of 

We searched PubMed and bioRxiv/medRxiv to identify all papers describing testing (including reverse transciption polymerase chain reaction assays/serology/radiology), treatment (including vaccines, at clinical phase only) or prognosis (predictors of clinical or viral outcomes) of COVID-19

( Figure 1 ). The search strategy for both databases is presented in Appendix 1. The PubMed search was run on 20th March 2020 and the bioRxiv/medRxiv search completed on 24th March 2020. Only articles published in English were considered for the purposes of the review. Further articles were identified through knowledge of the author team, reference and citation lists, and from any systematic reviews identified. Each article was screened by either FEL or ET on the basis of the title and abstract. Small workgroups focussing on testing, treatment and prognosis examined the full text articles within these topic areas and determined which studies provided relevant evidence. Any uncertainty about inclusion was resolved by discussion. Articles identified by this electronic search were combined with key clinical practice guidelines from expert groups and with relevant grey literature.

We included a total of 22 studies relating to testing: nineteen cohort studies of reverse-transcription polymerase chain reactions (RT-PCR) (9), serological testing (5) and combination testing (5) and

three cross-sectional studies. Studies of the development and optimisation of current and novel laboratory techniques were excluded given the clinical focus of this review.

The World Health Organisation recommend testing of all suspected cases for COVID-19 (Box 1) [31] .

The gold standard is RT-PCR to detect COVID-19 ribonucleic acid (RNA). Specimens can be upper respiratory (nasopharyngeal or oropharyngeal swab) or lower respiratory (sputum or endotracheal aspirate or broncho-alveolar lavage), although viral RNA has been detected in blood, anal swabs [32] , stool [33] [34] [35] , urine [36, 37] and in the conjunctival sac [38].

RT-PCR has good sensitivity (95%) and specificity (100%) at low numbers of COVID-19 RNA copies and against 297 samples of human respiratory and endemic human coronaviruses [39] . However, when applied clinically, a negative covid-19 PCR test may not be sufficient to rule out infection in suspected cases. There is discordance between negative respiratory swabs with detected viraemias, sputum samples and broncho-alveolar lavage [40, 41] . Initial PCR-negative suspected patients have subsequently become positive on repeat testing [42] [43] [44] [45] . Poor specimen quality, specimens collected in very early or late disease or sample handling issues may explain these false negative results, and in clinical practice RT-PCR sensitivity is reported to be 60-70% [45, 46] . Therefore, a negative result in a suspected case does not rule out COVID-19 infection [31] , and repeat testing may be advisable.

The cohort and cross-sectional studies describing the sensitivity of PCR defined suspected cases as those presenting with fever, respiratory presentations, imaging findings consistent with COVID-19 or case contact [33, 34, 47] . The sensitivity of RT-PCR for diagnosing COVID-19 following alternative presentations in older people e.g. delirium or fall, is unknown. None of the studies commented on whether sensitivity of RT-PCR was affected by age and with the exception of one cohort study [41] , the populations involved were younger hospitalised patients. The sensitivity of RT-PCR in older patients being cared for in different environments is unknown.

Understanding viral load dynamics throughout the COVID-19 disease course is important for interpreting RT-PCR results. PCR detects a higher viral load [33] and is more likely to be positive in earlier phases of the disease [48] . Although PCR tests become negative after viral clearance [19] , the time frame of this remains unclear and positive RT-PCR has been shown to persist beyond symptom resolution [19, 48] . One study described 7 patients who were discharged following 2 negative RT-

PCR tests, but after 2 weeks follow up had positive results [50] . There remains controversy as to whether persistent positive RT-PCR detection of COVID-19 after symptom resolution represents ongoing infectivity. Woelfel et al readily isolated live virus from respiratory samples taken in the first

week of symptoms but were not able to isolate live virus after 8 days despite detecting ongoing high viral RNA loads [49] .

Serological tests of the immunological response to COVID-19 have also been developed and have demonstrated positive IgM and IgG in PCR-negative patients. This could represent better sensitivity than PCR, or lower specificity of serology [47, 50] . The utility of serological analysis as a diagnostic test for COVID-19 depends on the dynamics of the immunological response. Several large population studies have shown low sensitivity of serology in the first 5-7 days of the illness, with this increasing steadily as the disease progresses up to positive results of 90-100% between 12 and 20 days since following symptom onset [40, 43, 51, 52] . Although one study examined the use of serological testing in an outpatient setting in younger patients [54] , there are currently no studies examining the sensitivity or dynamics of serological testing for COVID-19 in older populations in hospital or community settings.

Characteristic radiological images have also been considered as diagnostic tools for COVID-19 given the lack of sensitivity of PCR and serological tests in early disease [53] . However, CT sensitivity is also dependent on the time course of symptoms. One study of hospitalised patients with a mean age of 51, found 97% positive CT chest findings in 1014 RT-PCR-positive COVID-19 patients, but also 75% positive CT chest findings in RT-PCR negative patients. The study reported a sensitivity of 97% with 68% accuracy and 25% specificity. Furthermore, they found that in a subgroup who tested negative and then positive with serial (repeated) RT-PCR, a large proportion (67%, 10/15) had positive initial chest CT although this only accounted for only 15.6% of those presenting with typical CT features at the time of the initial negative RT-PCR [45] . A retrospective study of 64 COVID-19 PCR-positive patients with a mean age of 56 in Hong Kong, showed that 69% of patients had CXR changes at presentation. They compared CXR at presentation with RT-PCR disease confirmation on serial testing. Presentation CXR changes had a sensitivity for detecting COVID-19 of 69% compared to 91%

for presentation RT-PCR [53] . Multi-parameter screening tools are now being developed, which consider epidemiological factors, clinical features, radiological findings, and biochemical markers to

predict a diagnosis of COVID-19 [56] . No study has reported the diagnostic or prognostic role of imaging (CXR or CT) independent of the clinical parameters and/or biochemical parameters.

Rapid and accurate diagnosis of COVID-19 remains important to facilitate case isolation and, in older people, prognostication and advance care planning. The sensitivity of testing is dependent on disease stage, specimen site and quality. The clinical utility is further limited by test availability and delays in receiving results. In a health service faced with a rapidly increasing case load of patients with COVID-19, information from these different testing modalities can be incorporated to support diagnosis. We stongly advocate adopting a low threshold for testing older people with atypical symptoms where the result would alter management at an individual or population level. We recognise the lack of specific evidence on sensitivity of diagnostic tools in older people, testing in different care settings, and with varying symptom constellations e.g. dominance of lower or upper respiratory tract symptoms, as well as in those who are asymptomatic and / or contacts of positive cases.

We identified two management guidelines [55, 56] , four completed small-scale exploratory trials [57] [58] [59] [60] , four case series [12, [61] [62] [63] , three retrospective reviews [64] [65] [66] , and one rapid review of the effectiveness of antivirals [69] . Of the four trials, three reported experience with antivirals [58] [59] [60] and one with convalescent plasma [57] . The four case series reported experience with combination antivirals, corticosteroids, immunoglobulins and traditional Chinese medicine [12, [61] [62] [63] . Two of the retrospective reviews reported on the use of corticosteroids [64, 65] while one compared the treatment of older (>65 years) and younger patients. In addition, we were already aware of three [76] .

Gautret and colleagues conducted an open label non-randomised trial in France with 46 people (mean age 45 years, SD 22, (three >75 years)) using hydroxychloroquine and azithromycin and reported reduced viral loads at day 6 within the treatment group [61] . However, significant concerns have been raised about the methodological approach including the lack of control group and analysis whereby the results are likely to be confounded [77] . Chen and colleagues conducted an open label

randomised superiority trial in China comparing the efficacy of favipiravir and arbidol in 240 people (median age 46 years, IQR 34-59 (70 > 65 years)) with confirmed COVID-19 pneumonia [62] . At seven days, clinical recovery was higher in those on favipiravir but side effects of abnormal LFTs, psychiatric symptoms and GI upset were also more frequently reported [62] . Li and colleagues conducted an exploratory randomised controlled trial of lopinavir/ritonavir versus arbidol versus no antiviral medication in China in 44 people (mean age 52, SD 15 years, proportion >75 years not stated) with moderate COVID-19, and found no clear benefit and some potential harm of lopinavir/ritonavir [60] .

Duan and colleagues reported the feasibility of using pooled convalescent plasma on 10 people (median age 53 IQR 45-60, (one>75 years without comorbidity)) with severe COVID-19 already on maximal therapy [57] . Viral load became undetectable in 7 out of 10 patients following the infusion.

No adverse events were reported. The authors felt the intervention was feasible and merited further study [57] .

Wang and colleagues reported reduction in fever and improved oxygen saturations in a retrospective review of 46 people (median age 54 IQR 48-64) with severe COVID-19 pneumonia given methylprednisolone [67] . Zhou and colleagues reported findings from a retrospective review of the outcomes of 10 hospitalised people (mean age 52, SD 15) who received low dose corticosteroids and immunoglobulins with the majority also receiving anti-virals and antibiotics. A subsequent short course of methylprednisolone and further immunoglobulins were given when their condition deteriorated with observed improvement in oxygen requirements and inflammatory markers (CRP) [66] .

The 

guidance on using a cautious intravenous fluid strategy in those with confirmed or suspected COVID-19 [47] .

The current evidence for the effectiveness of antiviral, corticosteroid and immunotherapies is inconclusive, and previous experience from the treatment of other viral pneumonias points to the risk of potentially significant side effects. This is particularly the case for corticosteroids where experience from RSV, influenza, and MERS-CoV shows no clear benefit while observational data point towards increased mortality and secondary infection rates [58] . On this basis, current guidance advocates using corticosteroids only to treat co-existing disease e.g. chronic obstructive pulmonary disease (COPD) and sepsis rather than COVID-19 infection / complications. The timings of therapy may be important such that anti-virals are utilised to reduce the viral load in early disease with corticosteroids or anti-inflammatory therapies having a role in reducing immunopathological damage that contributes to mortality as the disease progresses.

Limited data on the use of antivirals and corticosteroids in older age groups have been published.

We identified one retrospective review which compared the treatments and escalation requirements of 136 older, defined as >60 years, (mean age 68, SD 7) and 652 younger (mean age 41, SD 11) patients with COVID-19 infections [66] . The older group were more likely to have a severe infection (24% vs 7% P<0.001), were more likely to need ICU admission (10% vs 1% P<0.001) and

were more likely to require mechanical ventilation (7% vs 1% p=0.001). The difference in the proportions that received antiviral medications (86% vs 84% p=0.622) may have occurred by chance but corticosteroids were given more often in the older group (27% vs 9% p<0.001) reflecting their disease severity. More older people remained in hospital at the end of the review period than younger people (23% vs 45% p<0.001) [66] . Despite the urgency to identify effective treatments for COVID-19 it is imperative that this does not undermine the necessary rigor of therapy evaluation, and it is with some concern that we note the reports of the inclusion of unproven antiviral agents in national guidelines for the treatment of COVID-19 [78] . Of note, the majority of the studies identified in this review predominantly included younger people. Their applicability to older people, and populations in countries and healthcare systems outside China is therefore unclear. Future studies must prioritise the inclusion of older people to ensure that any findings are valid in the population most at risk of negative outcomes.

We identified 13 retrospective cohort studies of patients with COVID-19 that looked at prognosis.

These studies examined the prognostic ability of one or more baseline factors to predict subsequent

COVID-19-related outcomes such as death, progression of disease severity, discharge from hospital or viral clearance studies (see Table 1 , and Appendix). Information on such factors should help direct the most effective treatment to those for whom it has the potential to offer meaningful benefit.

Eleven of the studies used traditional statistical epidemiology methods such as Cox regression and logistic regression, while two employed machine learning. Eight of the studies examined prognosis according to age. Not surprisingly, they all found that older patients had a worse prognosis: one large study observed the death rate to be more than double in the over 65s (hazard ratio 2.43, 95%

confidence interval 1.66 to 3.56) [4] . Five studies reported prognosis by gender and all observed males to have a worse prognosis than females. Several specific comorbidities have been reported to predict poorer outcomes, including body mass index (BMI), hypertension, diabetes, COPD, coronary heart disease and malignant tumours. Furthermore, patients with two or more comorbidities have a poorer prognosis than patients with one [8] .

Several symptoms were observed to predict outcomes. Higher levels of fever and higher respiratory rate in particular are associated with increased rates of progression or mortality, findings that have been replicated within or across studies. Numerous laboratory findings have also been observed to be prognostic, with higher white blood cell counts, lower lymphocyte counts, higher creatinine, higher creatine kinase, higher C-reactive protein, lower albumin, higher IL-6, higher myoglobin, higher lactate dehydrogenase, higher procalcitonin, higher high-sensitivity cardiac troponin I, higher total bilirubin, higher urea and presence of acute kidney injury, being characteristics consistently associated with worse prognosis across two or more studies. Future analysis of sequential measurements should help determine the trajectory of change and whether elevated levels in early disease are indicative of later deterioration.

The two studies using machine learning each identified a specific set of predictors. Bai [75] or CURB65 >1 and should prompt consideration of hospital admission [57] . However, the majority of prediction studies examining risk of hospitalisation, diagnosis of COVID-19 in those with symptoms and prognosis have been based on data from China. All have had a high risk of bias such that the prediction performance of tools in clinical practice is likely to be lower than initially reported [80] .

In the absence of proven treatments for COVID-19, current management is essentially supportive.

Older people living with frailty (clinical frailty score of 5 or more) presenting with COVID-19 should 

Comprehensive review of all non-drug interventions for COVID-19 infection were beyond the scope of this review. Recognising, however, that social distancing has a significant impact on older people we conducted a supplementary search to specifically consider the potential negative consequences of social distancing in older adults, using terms such as social distancing, social isolation, older adults and elderly.

In the current absence of preventative pharmaceutical interventions, such as vaccines and antivirals, classic public health measures are required to reduce and prevent person-to-person transmission, namely: isolation and quarantine, social distancing and community containment [84] .

Isolation and quarantine of ill, or possibly ill, individuals can be effective tools for preventing onwards transmission if early detection of cases is possible, as successfully implemented during the 2003 SARS epidemic [84] . Stricter measures of 'social distancing' and even more stringent 'community containment' may be deployed if community transmission, without obvious linkages between cases, is evident [84] . With evidence of widespread community transmission of COVID19, community containment ('lockdown') and social distancing has already been implemented in several countries. For older adults, the focus is on shielding such individuals from infection, because attack rates have been shown to be higher, and the disease more severe, in this age group [87] . Such measures, however, are highly disruptive for individuals and may have negative unintended consequences.

There is evidence that socially disconnected and isolated older adults are at increased risk of physical and mental health problems including cardiovascular disease, stroke, depression, anxiety, dementia and premature death, and as a result can require additional health and social care support [88] [89] [90] [91] [92] . 

p<0.05) [95] . Those experiencing a high degree of loneliness have been found to be at increased risk of becoming physically frail. Gale et al investigated the association between loneliness and prefrailty and frailty in 2,346 English older adults and found multivariable adjusted relative risk ratios of 

Larger scale trials relating to COVID-19 are a priority and are now underway including the multi-arm trials SOLIDARITY run by the WHO [97] and Randomised Evaluation of COVID-19 Therapy (RECOVERY) [98] . These will examine some of the drugs identified as promising in early studies excluding over-75s. Given the apparent increased risk of negative health outcomes in older people, it

is important that this vulnerable group is included in intervention trials with consideration given to age-related physiological, pharmacokinetic, pharmacodynamic changes and concurrent comorbidity.

The emergence of COVID-19 represents a dynamic, specific and real threat to the health and wellbeing of older people. The scope of COVID-19 is such that ethical support is being proposed to aid in the decisions on critical care [98, 99] , and the rapid NICE guidelines [70] suggest the use of the CFS in triage. These aspects combined with the compelling evidence that advanced age is a prognostic indicator for poorer outcome provides a clear basis on which guidance on the management of COVID-19 in older people is warranted [100, 101] . The research field is rapidly evolving as understanding of the clinical characteristics, transmission, and necessary public health and interventional measures becomes clearer. Recognising the real need for clinicians on the front lines to have reliable information, we have sought to rapidly synthesise and summarise the current evidence base of testing, treatments and prognostic factors, in addition to detailing the clinical and radiological features of the disease. Finally, we have provided a synopsis of the field of prospective clinical trials, with specific reference to the age-specific inclusion criteria.

One of the strengths of this paper has been the rapid screening of more than 1000 articles. In reports. Evidence that has not been peer reviewed should be considered within that context and the findings interpreted with caution. Furthermore, the reported results may be subject to reporting biases, and particularly to selective presentation of findings in the investigations of prognosis. The degree to which prognostic data from China is more widely generalisable is unknown and these data are not specific for older adults.

Our review has highlighted areas with a paucity of evidence that may be tackled with future research 

We strongly advocate that upper age limits in interventional trials are justified, and that awareness, 

settings to prevent the long-term adverse effects of COVID-19 may require specialist facilities or at least additional capacity to relieve pressure on acute services [108] . Data from survivors of acute respiratory distress syndrome (ARDS) and severe influenza A (H1N1) whom have been managed in intensive care settings suggests that the cognitive dysfunction and negative psychological sequalae including post-traumatic stress disorder, anxiety and depression in patients and families are common and should therefore provide a focus for intervention and evaluation. [109] We wholly support the public health measures that support reduction in COVID-19 transmission.

Effectiveness of future public health interventions such as vaccination, shielding and potential prophylactic treatments should include robust evaluation of unintended but potentially inevitable negative sequalae. Social distancing and isolation offer both protection and risk to some of the most vulnerable individuals in society. Future focus on aspects such as loneliness, deconditioning, progression of frailty and neglect of comorbidities are warranted as well as measures that might mitigate these harms.

The COVID-19 pandemic presents emergent and novel challenges as it evolves. Our review has highlighted areas within the domains of testing, treatment and prognostication that warrant future study. It will be imperative that research is proactively inclusive of older people so as to optimise prevention, treatment and rehabilitation strategies in this at-risk group.

A suspected case is: A. a patient with acute respiratory illness (that is, fever and at least one sign or symptom of respiratory disease, for example, cough or shortness of breath) AND with no other aetiology that fully explains the clinical presentation AND a history of travel to or residence in a country, area or territory that has reported local transmission of COVID-19 disease during the 14 days prior to symptom onset OR B. a patient with any acute respiratory illness AND who has been a contact of a confirmed or probable case of COVID-19 disease during the 14 days prior to the onset of symptoms (see the definition of contact below) OR C. a patient with severe acute respiratory infection (that is, fever and at least one sign or symptom of respiratory disease, for example, cough or shortness breath) AND who requires hospitalization AND who has no other aetiology that fully explains the clinical presentation.

Clinical Manifestations  Fever [7]  Dry Cough [7]  Dyspnoea  Myalgia  Fatigue  Diarrhoea [17]  Asymptomatic [110]  Acute Respiratory Distress Syndrome [7, 17]  Atypical presentations (e.g. behavioural change, balance problems, falls), particularly in older adults  Anosmia [9] Typical biochemical Findings (not exhaustive) [17, 19]  Lymphopenia  Elevated C-reactive protein Identification of the diagnostic accuracy, indication and optimal method(s) for testing in older people in the presence and absence of symptoms and in different settings e.g. primary versus secondary care, residential and nursing homes.

Evaluation of the extent to which frailty, comorbidity, and age and specific drugs (e.g. ACE inhibitors, non-steroidal anti-inflammatories (NSAIDs) and others e.g. immunosuppressants) influence the clinical presentation and disease trajectory of COVID-19 in older people. Ascertainment of the longer-term morbidity with evaluation of physical, cognitive and psychosocial outcomes.

Ongoing monitoring and advocacy to ensure that randomised clinical trials recruit older adults and that their enrolment is facilitated. Rapid implementation and evaluation of established and novel rehabilitation strategies are required to support post-acute care of older patients with COVID-19 infection. Evaluation of the advanced care planning discussion, documentation and communication along with optimal treatment strategies at the end of life.

Ascertainment of the impact of public health measures, particularly social isolation, on older people is warranted to determine the relative risks versus benefit of these strategies. Evaluation of multidisciplinary working across organisations to optimise acute care and rehabilitation. 

Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease

Prognostic value of NT-proBNP in patients with severe COVID-19

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Kidney disease is associated with in-hospital death of patients with COVID-19

Global surveillance for COVID-19 caused by human infection with COVID-19 virus: interim guidance

In patients of COVID-19, what are the symptoms and clinical features of mild and moderate cases?

Clinical characteristics of 50466 patients with 2019-nCoV infection

Clinical Characteristics of Coronavirus Disease 2019 in China. The New England journal of medicine

Loss of smell and taste in combination with other symptoms is a strong predictor of COVID-19 infection

First Case of COVID-19 Infection with Fulminant Myocarditis Complication: Case Report and Insights

Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

Clinical and radiographic features of cardiac injury in patients with 2019 novel coronavirus pneumonia

The definition and risks of Cytokine Release Syndrome-Like in 11 COVID-19-Infected Pneumonia critically ill patients: Disease Characteristics and Retrospective Analysis

Coronavirus Disease 2019 in Geriatrics and Longterm Care: The ABCDs of COVID-19

troubles sanguins sont potentiellement des signes avant-coureurs de l'infection respiratoire du Covid-19 chez la personne âgée fragile 2020

Clinical Characteristics of 2019 Novel Infected Coronavirus Pneumonia：A Systemic Review and Meta-analysis

Managing delirium in confirmed and suspected cases 2020

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

The Clinical and Chest CT Features Associated with Severe and Critical COVID-19 Pneumonia

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. The Lancet Infectious diseases

Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia. Radiology

Clinical and High-Resolution CT Features of the COVID-19 Infection: Comparison of the Initial and Follow-up Changes

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive care medicine

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory medicine. 2020. 29. EuGMS

COVID-19 in Older Adults: Key Points for Emergency Department Providers

Laboratory testing for coronavirus disease ( C ID-19) in suspected human cases: interim guidance

Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerging microbes & infections

First 12 patients with coronavirus disease 2019 (COVID-19) in the United States

Application and optimization of RT-PCR in diagnosis of SARS-CoV-2 infection

Evidence for gastrointestinal infection of SARS-CoV-2

Diagnosis of Acute Respiratory Syndrome Coronavirus 2 Infection by Detection of Nucleocapsid Protein

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro surveillance : bulletin Europeen sur les maladies transmissibles

Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2

Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections

Optimizing diagnostic strategy for novel coronavirus pneumonia, a multi-center study in Eastern China

Chest CT for Typical 2019-nCoV Pneumonia: Relationship to Negative RT-PCR Testing

Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease

Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2) infected pneumonia (COVID-19)

A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients

Clinical presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in a travelassociated transmission cluster

Association between Clinical, Laboratory and CT Characteristics and RT-PCR Results in the Follow-up of COVID-19 patients

Clinical significance of IgM and IgG test for diagnosis of highly suspected COVID-19 infection

Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice

A simple magnetic nanoparticles-based viral RNA extraction method for efficient detection of SARS-CoV-2

Serological detection of 2019-nCoV respond to the epidemic: A useful complement to nucleic acid testing

Frequency and Distribution of Chest Radiographic Findings in COVID-19 Positive Patients

COVID-19 early warning score: a multi-parameter screening tool to identify highly suspected patients

Diagnosis and clinical management of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection: an operational recommendation of Peking Union Medical College Hospital (V2.0). Emerging microbes & infections

A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)

The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study

An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI)

Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial

Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial

Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment

Clinical features and outcomes of 221 patients with COVID-19 in Wuhan, China

Epidemiological and clinical features of 291 cases with coronavirus disease 2019 in areas adjacent to Hubei, China: a double-center observational study

Short-Term Moderate-Dose Corticosteroid Plus Immunoglobulin Effectively Reverses COVID-19 Patients Who Have Failed Low-Dose Therapy

low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China

Analysis of Epidemiological and Clinical features in older patients with Corona Virus Disease 2019 (COVID-19) out of Wuhan

Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected

Home care for patients with COVID-19 presenting with mild symptoms and management of their contacts: interim guidance

Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment

COVID-19: Managing the COVID-19 pandemic in care homes: BGS Good Practice Guide

Reply to Gautret et al. 2020: A Bayesian reanalysis of the effects of hydroxychloroquine and azithromycin on viral carriage in patients with COVID-19

Predicting COVID-19 malignant progression with AI techniques

Clinical Characteristics and Outcome of Medical Staff Infected with COVID-19 in Wuhan, China: A Retrospective Case Series Analysis

A machine learning-based model for survival prediction in patients with severe COVID-19 infection

Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal

Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive care medicine

Antibiotic prescribing in the context of COVID-19 pandemic 2020

Randomised Evaluation of COVID-19 Therapy

Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak

Evolving Epidemiology and Impact of Non-pharmaceutical Interventions on the Outbreak of Coronavirus Disease

Preventing social isolation in older people

Loneliness as a public health issue: the impact of loneliness on health care utilization among older adults

Social disconnectedness, perceived isolation, and symptoms of depression and anxiety among older Americans (NSHAP): a longitudinal mediation analysis

Social isolation, loneliness and health in old age: a scoping review

Social isolation and loneliness: the new geriatric giants: Approach for primary care

Social exclusion and well-being among older adults in rural and urban areas

Social exclusion, self-rated health and depression among older people in China: Evidence from a national survey of older persons

Social isolation and loneliness as risk factors for the progression of frailty: the English Longitudinal Study of Ageing

WHO launches global megatrial of the four most promising coronavirus treatments 2020

Covid-19 trials begin in the UK, Canada and Europe

World Health Organisation: International Clinical Trials Registry Platform Search Portal

Facing Covid-19 in Italy -Ethics, Logistics, and Therapeutics on the Epidemic's Front Line. The New England journal of medicine

A Framework for Rationing Ventilators and Critical Care Beds During the COVID-19 Pandemic

The life and death decisions of covid-19

WHO must prioritise the needs of older people in its response to the covid-19 pandemic

BGS. COVID-19: BGS statement on research for older people during the COVID-19 pandemic 2020

Solidarity" clinical trial for COVID-19 treatments

A Randomised, embedded, multi-factorial, adaptive platform trial for community-acquired pneumonia

COVID-19 Hospital Discharge Service Requirements

We need a Nightingale model for rehab after COVID-19

Report of an ad-hoc international task force to develop an expert-based opinion on early and short-term rehabilitative interventions (after the acute hospital setting) in Covid-19 survivors

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention

Influence factors of death risk among COVID-19 patients in Wuhan, China: a hospital-based case-cohort study

Clinical progression of patients with COVID-19 in Shanghai, China. The Journal of infection

Comorbidity and its impact on 1,590 patients with COVID-19 in China: A Nationwide Analysis

COVID-19 in a Designated Infectious Diseases HospitalOutside Hubei Province,China

Kidney impairment is associated with in-hospital death of COVID-19 patients

Epidemiological and clinical features of COVID-19 patients with and without pneumonia in Beijing, China

Association of Cardiovascular Manifestations with In-hospital Outcomes in Patients with COVID-19: A Hospital Staff Data